Lodi et al. create a pan-cancer single-cell atlas characterizing immune cell heterogeneity within the tumor microenvironment (TME). They identify 70 shared cell subtypes, some of which are spatially co-localized to form two distinct immune reactive TME hubs. Both hubs associate with improved checkpoint immunotherapy outcome across different cancer types.